Investors never know what to expect for Kensey Nash
What analysts say:
- Buy, sell, or hold?: Half of analysts think investors should stand pat on Kensey Nash while the remaining half rate the stock as a buy. Analysts like Kensey Nash better than competitor Wright Medical Group overall. Six out of 16 analysts rate Wright Medical Group a buy compared to three of six for Kensey Nash. Kensey Nash's rating hasn't changed over the past three months.
- Revenue forecasts: On average, analysts predict $19.3 million in revenue this quarter. That would represent a rise of 13.8% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.31 per share. Estimates range from $0.30 to $0.32.
What our community says:
CAPS All-Stars are solidly backing the stock with 78.9% giving it an "outperform" rating. The community at large agrees with the All-Stars with 83.3% awarding it a rating of "outperform." Fools have embraced Kensey Nash, though the message boards have been quiet lately with only 38 posts in the past 30 days. Kensey Nash's bearish CAPS rating of two out of five stars falls short of the Fool community sentiment.
Revenue has fallen for the past three quarters. The company's gross margin shrank by 11.7 percentage points in the last quarter. Revenue fell 14.5% while cost of sales rose 23.3% to $7.1 million from a year earlier.
One final thing: If you want to keep tabs on Kensey Nash movements -- and for more analysis on the company -- make sure you add it to your Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.